FDA Approves Novel Anticoagulant Savaysa

Share this content:
FDA Approves Novel Anticoagulant Savaysa
FDA Approves Novel Anticoagulant Savaysa

(HealthDay News) -- Savaysa (edoxaban) has been approved by the U.S. Food and Drug Administration to reduce the risk of stroke and systemic embolism, and prevent deep vein thrombosis and pulmonary embolism.

The drug was approved for people with atrial fibrillation that isn't caused by a heart valve problem, and for people with deep vein thrombosis or pulmonary embolism, the FDA said in a news release.

Clinical studies compared Savaysa to warfarin. The newly-approved drug was found as effective as warfarin in preventing stroke, but had significantly fewer cases of major bleeding episodes that can affect warfarin patients, the FDA said.

Nonetheless, bleeding was recorded as a primary side effect of Savaysa, as was anemia. Savaysa's label will include a boxed warning that the drug may be less effective among people with a creatinine clearance greater than 95 milliliters per minute. The advisory also warns that sudden discontinuation of Savaysa increases the risk of stroke.

Savaysa is made by the Japanese pharmaceutical company Daiichi Sankyo, based in Tokyo.

More Information

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease



Sign up for myCME e-newsletters




More in Home

Some California Mosquitoes Can Carry Zika Virus

Some California Mosquitoes Can Carry Zika Virus

Aedes aegypti mosquitoes found to transmit Zika virus

Periodontal Inflammation a Risk With Tongue Piercing

Periodontal Inflammation a Risk With Tongue Piercing

And, two young females with tongue piercings have deep lingual infrabony lesions, periodontitis

Risk of OD Highest for First Days of Opioid  Benzodiazepine Use

Risk of OD Highest for First Days of ...

Five-fold increased risk of opioid-related overdose during first 90 days of concurrent use

is free, fast, and customized just for you!




Already a member?

Sign In Now »